$SXTP

AstraZeneca (AZN) and Daiichi Sankyo (4568.T) won EU approval for Enhertu in breast cancer. Pfizer (PFE) expanded Talzenna-Xtandi use in prostate cancer. AbbVie (ABBV) got FDA approval for subcutaneous SKYRIZI in Crohn's disease. Artiva (ARTV) to cut 94% of workforce after halting AlloNK development. Tango (TNGX) plans 14% layoffs. Rakovina (RKV.V) and Celvion used AI to prioritize cancer types for ATR inhibitor. 60 Degrees (SXTP) partners for alpha-gal syndrome research.

60 Degrees Pharmaceuticals (SXTP) partners with The University of Southern Mississippi to research castanospermine as a potential treatment for alpha-gal syndrome, a tick-borne allergy. The company funds the study and has an option to commercialize any resulting intellectual property. SXTP stock is up 10.69% to $0.81, trading between $0.58 and $8.62 over the past year.

60 Degrees Pharmaceuticals (SXTP) reported clinical improvement and negative PCR results in all five patients completing its babesiosis study. 80% also tested negative on a sensitive assay. Two more patients are ongoing, with enrollment at seven. The company plans to unblind a separate study in January 2027 and seek FDA pre-approval discussions.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on

60 Degrees Pharmaceuticals (SXTP) updated investors on tafenoquine for babesiosis, noting a blinded study to unblind in January 2027, three confirmed cures, and a potential 2027 FDA filing. Early chronic-study screening showed genus-level signals in 2 of 9 patients, but no positive B. microti results.

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Tafenoquine for Babesiosis Progress across acute, relapsing and chronic disease Geoffrey S. Dow, PhD Chief Executive Officer 2026 ILADS Annual Scientific Conference October 22–25, 2026 | Herndon, Virginia Reframing Complex Disease: Pathways to Treatment 2026 update A

60 Degrees Pharmaceuticals (SXTP) will unblind its hospitalized babesiosis study after enrolling 30 patients. The company expects results in January 2027 and plans to discuss regulatory pathways with the FDA. No safety signals were identified, and an expanded-access study supports potential molecular cures.

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tafenoquine for Severe Babesiosis Study Interim Data Readout Webinar October 6, 2026 Today's discussion • Clinical context and current standard of care • Published evidence supporting tafenoquine + atovaquone • Hospital study interim analysis and DSMB feedback • Next

60 Degrees Pharmaceuticals (SXTP) shares rose 18% ahead of interim data release from its Phase 2 study of tafenoquine for severe babesiosis. The study, involving at least 24 patients, evaluates tafenoquine with standard care. No FDA-approved treatment exists for babesiosis, a tick-borne disease. SXTP's stock traded between $0.84 and $8.62 in the past year, closing Monday at $1.44.